| 000 | 01766 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516075504.0 | ||
| 264 | 0 | _c20120523 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1742-1241 | ||
| 024 | 7 |
_a10.1111/j.1742-1241.2011.02806.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, T | |
| 245 | 0 | 0 |
_aComparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. _h[electronic resource] |
| 260 |
_bInternational journal of clinical practice _cApr 2012 |
||
| 300 |
_a399-408 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAlendronate _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMulticenter Studies as Topic |
| 650 | 0 | 4 |
_aOsteoporosis, Postmenopausal _xdrug therapy |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aWang, C | |
| 700 | 1 | _aCai, X-Z | |
| 700 | 1 | _aZhao, X | |
| 700 | 1 | _aShi, M-M | |
| 700 | 1 | _aYing, Z-M | |
| 700 | 1 | _aYuan, F-Z | |
| 700 | 1 | _aGuo, C | |
| 700 | 1 | _aYan, S-G | |
| 773 | 0 |
_tInternational journal of clinical practice _gvol. 66 _gno. 4 _gp. 399-408 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1742-1241.2011.02806.x _zAvailable from publisher's website |
| 999 |
_c21526062 _d21526062 |
||